Kornimate/medical-research-clean huggingface dataset:
anti-bacterial potential of nano calcium hydroxide as an intracanal medication

Conditions: Endodontic Disease; Pulp Disease, Dental

Summary: the aim of the study is to evaluate the anti-bacterial potential of nano calcium hydroxide as an intracanal medication in primary endodontic treatment of permanent molars.

this study is conducted to evaluate the bacterial reduction capability of hydrogel loaded with nano calcium hydroxide and paste form of nano and conventional calcium hydroxide as an intracanal medication. the hydrogel will be synthesized in a new rapid in situ form that can turn from liquid into gel when reaching body temperature. the efficacy of bacterial reduction will be compared with nano calcium hydroxide and conventional calcium hydroxide in paste form. the evaluation is to be done by quantitative microbiological assessment of samples which are gained from the root canal before and after intracanal medication placement in roots of permanent molars, having pai score ≥ 2.

Eligibility criteria:
inclusion criteria: * healthy males and females. * age range between 21-49. * patients with no physical disability or psychological problems. * patients presenting with single permanent molar with signs and/or symptoms of apical periodontitis, and having periapican index ≥ 2. exclusion criteria: * pregnant women. * patients with immune-compromised disease. * patients with complicated systemic diseases. * patients who took antibiotics within a period of 1 month. * patients with known sensitivity to the medicaments or pharmaceuticals used in this study. * non-restorable teeth including root fractures, and/or advanced periodontal involvement.

Keywords: intracanal medication
extracorporeal membrane oxygenation effect in prolonged cardiopulmonary resuscitation

Conditions: Cardiopulmonary Resuscitation; Cardiac Arrest; Ventricular Tachycardia; Ventricular Fibrillation

Summary: analysis of the patients' data who were rescued with extracorporeal membrane oxygenation and without ecmo. the survival rate and the weaning rate were analyzed to see the effect of ecmo on the prolonged cpr.


Eligibility criteria:
inclusion criteria: * cpr \> 10 min without return of spontaneous circulation exclusion criteria: * cpr with traumatic origin unless bleeding was under control, previous irreversible brain damage, terminal status of malignancy, and the age over 75 years. for the patients with post-cardiotomy shock requiring ecls in the operating theater because of an inability of weaning from cardiopulmonary bypass, they were excluded as well from this ecpr cohort since they did not receive cardiac massage. the patients that had signed "do-not-resuscitate" (dnr) consent were also excluded from ecls deployment.

Keywords: ecmo cpr
study in healthy tubal ligated women to evaluate pharmacodynamics, safety and pharmacokinetics of bay1002670

Conditions: Leiomyoma

Summary: effects of bay1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian function; return of menstrual bleeding after treatment; safety and tolerability; pk/pd (pharmacokinetic/pharmacodynamic) relationship


Eligibility criteria:
inclusion criteria: * healthy female subjects * sterilized by tubal ligation * age 18-45 years * body mass index (bmi) at screening: ≥ 18 and ≤ 32 kg/m² * at least 3 consecutive regular menstrual cycles with a cycle length of 24 - 35 days before first screening examination according to the subject's history * absence of clinically relevant abnormal findings in the pre-treatment endometrial biopsy exclusion criteria: * regular use of medicines (incl. anabolics) * incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal * amenorrhea for more than 3 months within the last 6 months before the first screening examination * lacking suitability for frequent transvaginal ultrasonography (tvu) examinations * clinically relevant findings (e.g. blood pressure, electrocardiogram \[ecg\], physical and gynecological examination, laboratory examination)

Keywords: pk/pd bay1002670
an adipocyte-driven mechanism for weight regain after weight loss: the yo-yo effect

Conditions: Obesity; Weight Loss; Diet

Summary: almost half of the dutch population is currently characterized by overweight and obesity. losing weight is not the problem in obesity treatment, it is the seemingly obligatory weight regain after weight loss: the yoyo-effect. the primary objective of this study is to investigate the association between the weight-loss-induced cellular stress response and the rate of weight regain. the secondary objective is to investigate the differences in cellular stress response and weight regain after rapid and slow weight loss. to investigate this, subjects will receive meal replacements replacing either all or part of the daily meals during the intervention period. the first group will consume 500 kcal/d diet for 5 weeks while the second group consumes a 1250 kcal/d diet for 3 months, both followed by 1 week normalization and a 2 week strict weight maintenance diet. during the 9-month follow-up period subjects will receive dietary advice according to the dutch recommendations for healthy eating. the association between the amount of weight regain after the weight loss period and changes in adipokines, parameters of adipocyte metabolism, in vivo adipose tissue metabolism, adipocyte extracellular matrix gene expression profiles, adipocyte stress protein expression and gene polymorphisms in selected genes.


Eligibility criteria:
inclusion criteria: * age (years): 20-65 * body mass index (kg/m2): 28-35 * non-smokers exclusion criteria: * subjects using prescription medication, or suffering from diseases or conditions that might influence the outcome of the study: this concerns diseases/medication that influence body weight regulation (malabsorption, untreated hypo/hyperthyroidism, eating disorders, systemic use of steroids, etc.) and obesity-related cardiovascular risk factors (heart disease, systolic and diastolic blood pressures \> 160/100 mmhg, blood glucose \> 6.1 mmol l-1, blood cholesterol \> 7 mmol l-1, blood triglycerides \> 3 mmol l-1) * marked alcohol consumption \> 21 alcoholic units week-1 (male), or \>14 alcoholic units week-1 (female) * planned major changes in physical activity during the study to an extent that might interfere with the study outcome as judged by the investigator; * blood donation within the past 2 months prior to the study * weight change of \>3 kg within 2 months prior to the study * psychiatric disease (based on medical history only) * pregnant or lactating women, or women planning to become pregnant within the next 12 months * surgically treated obesity * participation in other clinical studies within the last 3 months * drug abuse (based on clinical judgment) * unable to give informed consent * unable to engage in a low-calorie diet * unable to lose more then 8% of body weight after weight-loss period * following a special diet (vegetarian, atkins or other).

Keywords: adipocytes
adolescent pcip randomized feasibility trial

Conditions: Post-Traumatic Stress Disorder in Adolescence; Post Traumatic Stress Disorder

Summary: there are three research questions: (1) whether the primary care intervention for ptsd (pcip) improves health outcomes; (2) whether and how the pcip can be sustainably delivered via telehealth; and (3) how pcip compares to treatment as usual (tau) participants. the mixed methods randomized feasibility trial of the protocol will be measured by the re-aim framework (reach, effectiveness, adoption, implementation, maintenance) (n=44 patients and their care givers). we will collect data on patient, caregiver, and clinic staff participation, retention, and satisfaction (reach and adoption), change in hypothesized treatment mechanisms and symptoms (effectiveness), and facilitators and barriers to intervention delivery and fidelity (implementation). we will, 1. assess the reach and adoption of the protocol by analyzing quantitative data on patient and clinic staff participation, retention, and satisfaction; 2. explore the effectiveness of the protocol through medical record review, quantitative assessments at baseline and post-treatment, and semi-structured qualitative interviews at baseline and post-treatment to: 3. evaluate the implementation of the screening and intervention protocol with post-intervention semi-structured qualitative interviews to assess facilitators and barriers to intervention delivery, quantitative fidelity scales, observation of screening, and review of intervention audio recordings to assess fidelity to the protocol and intervention process.


Eligibility criteria:
inclusion criteria: 1. patient referred to the shark program 2. patients must be at least 12 years old 3. screened for probable ptsd on ucla ri, or at provider discretion of clinical relevancy. 4. if patient is under 18 years old, the patient's legal guardian is able and willing to provide informed consent for the patient to participate in the study; 5. patient is able to complete study activities in english. exclusion criteria: 1. suicidal ideation with a plan within the last two weeks or a suicide attempt within the past 30 days; 2. inability to provide informed consent or assent, and/or complete procedures in english.

Keywords: adolescent primary care ptsd post traumatic stress disorder randomized feasibility trial tf-cbt
the effect of 10 repetitions of deep breathing exercises

Conditions: Heart; Surgery, Heart, Functional Disturbance as Result

Summary: the goal of this clinical trial is to learn and assess the effect of 10 repetitions of deep breathing exercises every 3 hours compared to 3 repetitions of deep breathing exercises on the sleep quality of patients after heart surgery. the main questions it aims to answer are: how does 10 repetitions of deep breathing exercises every 3 hours affect the sleep quality of patients after heart surgery? researchers will compare 10 repetitions of deep breathing exercises every 3 hours to 3 repetitions of deep breathing exercises to see if 10 repetitions of deep breathing exercises every 3 hours work to improve sleep quality. participants will: 1. respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days. 2. respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.

1. researchers carried out recruitment when the patient had undergone surgery. 2. researchers determine potential respondents who meet the inclusion criteria. 3. researchers explain to potential respondents the procedures, objectives, benefits and risks of the research being conducted. 4. researchers provide time and opportunity for potential respondents to confirm research procedures. 5. the researcher provided an informed consent sheet as a form of respondent's agreement to their involvement in the research. 6. researchers determine respondents for the intervention and control groups. 7. respondents do a pretest. the pretest was administered by administering a sleep characteristics and quality questionnaire. 8. researchers provide education to patients regarding deep breathing exercise procedures. 9. respondents in the intervention group performed deep breathing exercises with 10 repetitions every 3 hours for 3 days. respondents in the control group did 3 repetitions of deep breathing exercises. 10. respondents are monitored in the implementation process using a monitoring form. 11. respondents who completed the exercise will conduct a post-test assessment.

Eligibility criteria:
inclusion criteria: * patients who have undergone cardiac surgery, both on-pump and off-pump. * the patient's hemodynamic condition is stable. * more than equal to 18 years old. * able to communicate, read and write in indonesian. exclusion criteria: * patients who receive sleeping medication or sedative therapy.

Keywords: breathing exercise sleep quality cardiac surgical procedures
phase 2a placebo-controlled study of vtx3232 alone or in combination with semaglutide in obesity

Conditions: Obesity

Summary: this is a study to understand if taking vtx3232 alone or in combination with semaglutide is safe in participants diagnosed with obesity. approximately 160 patients will take vtx3232 dose a, placebo, vtx3232 dose a in combination with semaglutide, or placebo in combination with semaglutide. this study consists of a 30-day screening period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives vtx3232 dose a, placebo, vtx3232 dose a in combination with semaglutide, or placebo in combination with semaglutide), and a 30-day follow-up period. the maximum duration of treatment will be approximately 12 weeks.


Eligibility criteria:
inclusion criteria: * participants are male or female ≥ 18 years up to ≤ 80 years of age. * ability to comply with study requirements. * bmi ≥ 30.0 to ≤ 42.0 kg/m2 at screening. * stable body weight (± 5%) for at least 3 months prior to screening. * hs-crp ≥ 2 mg/l at screening. * hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy. * history of at least one self-reported unsuccessful dietary effort to lose body weight. exclusion criteria: * obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity * have any prior diagnosis of diabetes mellitus * current participation (or within the last 3 months) in an organized weight reduction program. * history or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect gi motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \[bariatric\] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity. * clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult. * use of any medication (e.g., glp-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study. * receipt of the following medications: 1. any immunosuppressive biologic or targeted therapy within 90 days prior to day 1. 2. use of anti-inflammatory medications within 30 days prior to day 1 3. colchicine within 30 days prior to day 1. 4. glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.

Keywords: nlrp3 inhibitor vtx3232 zomagen
study of pemetrexed and carboplatin compared with etoposide carboplatin to treat extensive-stage small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: this study is a phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. it is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of extensive stage small cell lung cancer (sclc) * capable of self-care but may be unable to carry out any work activities. * no prior anticancer therapy for sclc exclusion criteria: * have previously participated in a study involving pemetrexed * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication
a 12 day study to evaluate a topical drug to treat plaque psoriasis

Conditions: Psoriasis Vulgaris

Summary: this is a vehicle and comparator controlled proof of mechanism (pom) trial to evaluate the effect on psoriasis disease activity and safety of topically applied pf 06263276 in subjects with psoriasis vulgaris.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects age 18 years and older, inclusive. healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ecg or clinical laboratory tests. * subjects with psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas. * the target lesion(s) should be on the trunk or extremities (excluding palms/soles). psoriatic lesions on the knees or elbows are not to be used as a target lesion. exclusion criteria: * subjects with psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis arthropathica and pustular psoriasis. * treatment with any systemic medications which in the opinion of the investigator might counter or influence the trial aim (including anti psoriasis medications, eg, corticosteroids, cytostatics or retinoids) or medications which are known to provoke or aggravate psoriasis (eg, beta blocker, anti malarial drugs, lithium) or phototherapy/psoralen+uva (puva) within 4 weeks preceding the treatment phase of the trial and during the trial. * treatment with any locally acting medications (including anti-psoriasis medications like vitamin d analogues, dithranol) within 4 weeks of the treatment phase.

Keywords: psoriasis plaque vulgaris phase 1 randomized double-blind topical safety
effect of intraoperative nerve monitoring on voice quality during thyroid surgery

Conditions: Thyroid

Summary: "effect of intraoperative nerve monitoring on voice quality during thyroid surgery" thyroidectomy is a quite often surgical procedure applied by both head and neck surgeons and endocrine surgeons.recent advances in surgical and technological area achieve a remarkable decrease in the complication rates. in case of these advances, patients still have fear related with their voice. in this study, investigators aimed to investigate voice changes during thyroid surgery and effect of intraoperative nerve monitoring to the voice quality.

in order to minimize the complication rates and voice disturbances during thyroidectomy, intraoperative nerve monitoring(ionm) is a widely used intervention. in this study investigators will compare conventional surgery with ionm used surgery. randomly chosen half of the patients will be operated with ionm. vagus, recurrent and superior laryngeal nerves will be monitored during surgery and measured for nerve integrity . rest of the patients will be operated with standard conventional method. all participants will be analyzed with a computer program for their voice quality preoperatively and postoperatively at 14th day of surgery.

Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of nodular or multinodular goiter * clinical, radiological and pathologically diagnosed thyroid cancer * must be able to speak (for voice recording) exclusion criteria: * pregnancy * previous thyroid surgery * previous laryngeal operations * professional voice users (e.g. singers)

Keywords: thyroidectomy nerve monitoring
role of the catechol-o-methyltransferase (comt) in the physiological regulation of vigilance

Conditions: Healthy

Summary: in this study, pharmacologic effects of comt inhibition during sleep deprivation in healthy subjects in dependence of their val158met genotype of comt are studied. potential effects are identified by measurement of vigilance and cognitive performance as well as eeg measurements during wake and sleep. * trial with medicinal product


Eligibility criteria:
inclusion criteria: * healthy male subjects * age: 20-30 years * written informed consent * right handed * non smoker exclusion criteria: * sleep disturbances * irregular sleep-wake rhythm * travelling with time-shift * liver diseases (alt: \> 82 u/l; ast: \> 76 u/l) * diseases of the nervous system * acute internal medicine diseases * medication or drug abuse * intake of more than 3 caffeine-containing drinks * intake of more than 5 alcoholic drinks per week * heart pacemaker or implanted medical devices * body-mass-index (bmi): 20\ 26

Keywords: sleep-wake regulation volunteers
a pilot study to explore the role of gut flora in metastatic mesothelioma

Conditions: Mesothelioma; Mesothelioma Malignant; Mesothelioma; Lung; Mesotheliomas Pleural; Mesothelioma Peritoneum; Mesothelioma; Liver; Mesothelioma; Omentum

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to metastatic mesothelioma

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. may be signed by parent or legal guardian in the case of minor or adult unable to provide consent 2. male or female of all ages. (interest is given to children who present with autism or crohn's and whose parents wish to analyze their children's gut flora. also of interest analysis of development of the child's microbiome. in the case of autism, the younger the child, the better to correct the neurological problems if an association is found between autism and the microbiome) 3. diagnosis of metastatic mesothelioma through biopsy and/or advanced imaging exclusion criteria: 1. refusal to sign informed consent form 2. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 3. postoperative stoma, ostomy, or ileoanal pouch 4. participation in any experimental drug protocol within the past 12 weeks 5. treatment with total parenteral nutrition